"Revolutionary RNA Switch Offers Precise Control Over Gene Therapy"
Researchers at Baylor College of Medicine have developed a novel gene regulation system that can turn genes on or off using FDA-approved doses of small molecules like tetracycline. This system, which operates by controlling the cleavage of a polyA signal in the RNA, promises to make gene therapy safer and more controllable, allowing for precise adjustments of therapeutic protein levels according to patient needs. The absence of foreign regulatory proteins reduces the risk of immune responses, making this a significant advancement in the field of gene therapy.